Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 498

1.

The prevalence of pressure ulcers in Europe, what does the European data tell us: a systematic review.

Moore Z, Avsar P, Conaty L, Moore DH, Patton D, O'Connor T.

J Wound Care. 2019 Nov 2;28(11):710-719. doi: 10.12968/jowc.2019.28.11.710.

PMID:
31721669
2.

Reducing Cell-Free DNA and Neutrophil Extracellular Traps May Improve Outcomes of Orthotopic Liver Transplantation.

Moore DH, Shah NL.

Liver Transpl. 2018 Dec;24(12):1649-1650. doi: 10.1002/lt.25371. No abstract available.

3.

The Veterans Health Administration's Traumatic Brain Injury Screen and Evaluation: Service Delivery Insights.

Moore DH, Powell-Cope G, Belanger HG.

Mil Med. 2018 Sep 1;183(9-10):e494-e501. doi: 10.1093/milmed/usy036.

PMID:
29912463
4.

A Ternary Mixture of Common Chemicals Perturbs Benign Human Breast Epithelial Cells More Than the Same Chemicals Do Individually.

Dairkee SH, Luciani-Torres G, Moore DH, Jaffee IM, Goodson WH 3rd.

Toxicol Sci. 2018 Sep 1;165(1):131-144. doi: 10.1093/toxsci/kfy126.

5.

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ.

Lancet. 2017 Oct 7;390(10103):1654-1663. doi: 10.1016/S0140-6736(17)31607-0. Epub 2017 Jul 27.

6.

Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease.

Diana A, Pillai R, Bongioanni P, O'Keeffe AG, Miller RG, Moore DH.

Cochrane Database Syst Rev. 2017 Jan 9;1:CD006049. doi: 10.1002/14651858.CD006049.pub2. Review.

7.

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.

Moore KN, Java JJ, Slaughter KN, Rose PG, Lanciano R, DiSilvestro PA, Thigpen JT, Lee YC, Tewari KS, Chino J, Seward SM, Miller DS, Salani R, Moore DH, Stehman FB.

Gynecol Oncol. 2016 Nov;143(2):294-301. doi: 10.1016/j.ygyno.2016.08.317. Epub 2016 Aug 17.

8.

ACR Appropriateness Criteria® Adjuvant Management of Early-Stage Endometrial Cancer.

Wahl AO, Gaffney DK, Jhingran A, Yashar CM, Biagioli M, Elshaikh MA, Jolly S, Kidd E, Lee LJ, Li L, Moore DH, Rao GG, Williams NL, Small W Jr.

Oncology (Williston Park). 2016 Sep 15;30(9):816-22. Review.

9.

Phase I clinical trial of safety of L-serine for ALS patients.

Levine TD, Miller RG, Bradley WG, Moore DH, Saperstein DS, Flynn LE, Katz JS, Forshew DA, Metcalf JS, Banack SA, Cox PA.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):107-111. doi: 10.1080/21678421.2016.1221971. Epub 2016 Sep 2.

PMID:
27589995
10.

ACR Appropriateness Criteria® Management of Recurrent Endometrial Cancer.

Elshaikh MA, Vance S, Gaffney DK, Biagioli M, Jhingran A, Jolly S, Kidd E, Lee LJ, Li L, Moore DH, Rao GG, Wahl AO, Williams NL, Yashar CM, Small W Jr; Expert Panel on Radiation Oncology–Gynecology:.

Am J Clin Oncol. 2016 Oct;39(5):507-15. doi: 10.1097/COC.0000000000000318.

PMID:
27400117
11.

Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.

Tewari KS, Sill MW, Monk BJ, Penson RT, Long HJ 3rd, Poveda A, Landrum LM, Leitao MM, Brown J, Reid TJ, Michael HE, Moore DH.

Clin Cancer Res. 2015 Dec 15;21(24):5480-7. doi: 10.1158/1078-0432.CCR-15-1346. Erratum in: Clin Cancer Res. 2016 Aug 1;22(15):3983.

12.

ACR Appropriateness Criteria® Adjuvant Therapy in Vulvar Cancer.

Jolly S, Soni P, Gaffney DK, Biagioli M, Elshaikh MA, Jhingran A, Kidd E, Lee LJ, Li L, Moore DH, Rao GG, Wahl AO, Williams NL, Yashar CM, Small W Jr.

Oncology (Williston Park). 2015 Nov;29(11):867-72, 874-5.

13.

Perceptions of practice guidelines for people with spinal cord injury.

Powell-Cope G, Moore DH, Weaver FM, Thomason S.

Rehabil Nurs. 2015 Mar-Apr;40(2):100-10. doi: 10.1002/rnj.134. Epub 2013 Dec 9.

PMID:
25782593
14.

Exposure to the polyester PET precursor--terephthalic acid induces and perpetuates DNA damage-harboring non-malignant human breast cells.

Luciani-Torres MG, Moore DH, Goodson WH 3rd, Dairkee SH.

Carcinogenesis. 2015 Jan;36(1):168-76. doi: 10.1093/carcin/bgu234. Epub 2014 Nov 19.

15.

A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS.

Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, Ludolph A, Cudkowicz ME, van den Berg LH, Mather J, Petzinger T Jr, Archibald D.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):406-13. doi: 10.3109/21678421.2014.943672. Epub 2014 Aug 15.

PMID:
25125035
16.

Long-term outcomes among African-American and white women with breast cancer: what is the impact of comorbidity?

Izano M, Satariano WA, Tammemagi MC, Ragland D, Moore DH, Allen E, Naeim A, Sehl ME, Hiatt RA, Kerlikowske K, Sofrygin O, Braithwaite D.

J Geriatr Oncol. 2014 Jul;5(3):266-75. doi: 10.1016/j.jgo.2014.02.003. Epub 2014 Mar 5.

17.

Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells.

Sayeed A, Luciani-Torres G, Meng Z, Bennington JL, Moore DH, Dairkee SH.

PLoS One. 2013 Jun 20;8(6):e67191. doi: 10.1371/journal.pone.0067191. Print 2013.

18.

Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications.

Piper M, Peled AW, Foster RD, Moore DH, Esserman LJ.

Ann Plast Surg. 2013 Apr;70(4):435-7. doi: 10.1097/SAP.0b013e31827e5333. Review.

PMID:
23486127
19.

Response.

Arasu VA, Joe BN, Lvoff NM, Leung JW, Brenner RJ, Flowers CI, Moore DH, Sickles EA.

Radiology. 2013 Feb;266(2):685-6. No abstract available.

PMID:
23479783
20.

Reflections on vulvar tumors, lymphatic drainage, and sentinel lymph node biopsy.

Moore DH.

Gynecol Oncol. 2013 Feb;128(2):153-4. doi: 10.1016/j.ygyno.2012.12.042. No abstract available.

PMID:
23337403
21.

The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials.

Berry JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA, Dong Y, Ingersoll EW, Archibald D.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Apr;14(3):162-8. doi: 10.3109/21678421.2012.762930. Epub 2013 Jan 17. Review.

PMID:
23323713
22.

Do patients use decision and communication aids as prompted when meeting with breast cancer specialists?

Volz S, Moore DH, Belkora JK.

Health Expect. 2015 Jun;18(3):379-91. doi: 10.1111/hex.12042. Epub 2013 Jan 7.

23.

Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target.

Soroceanu L, Murase R, Limbad C, Singer E, Allison J, Adrados I, Kawamura R, Pakdel A, Fukuyo Y, Nguyen D, Khan S, Arauz R, Yount GL, Moore DH, Desprez PY, McAllister SD.

Cancer Res. 2013 Mar 1;73(5):1559-69. doi: 10.1158/0008-5472.CAN-12-1943. Epub 2012 Dec 13.

24.

Creatine for amyotrophic lateral sclerosis/motor neuron disease.

Pastula DM, Moore DH, Bedlack RS.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD005225. doi: 10.1002/14651858.CD005225.pub3. Review.

PMID:
23235621
25.

Bisphenol-A-induced inactivation of the p53 axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial cells.

Dairkee SH, Luciani-Torres MG, Moore DH, Goodson WH 3rd.

Carcinogenesis. 2013 Mar;34(3):703-12. doi: 10.1093/carcin/bgs379. Epub 2012 Dec 7.

26.

Infrasound sensitizes human glioblastoma cells to cisplatin-induced apoptosis.

Rachlin K, Moore DH, Yount G.

Integr Cancer Ther. 2013 Nov;12(6):517-27. doi: 10.1177/1534735412465641. Epub 2012 Nov 19.

PMID:
23165942
27.

Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival.

Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, Zhao W, Moore DH, Powell SZ, Appel SH.

EMBO Mol Med. 2013 Jan;5(1):64-79. doi: 10.1002/emmm.201201544. Epub 2012 Nov 9. Erratum in: EMBO Mol Med. 2013 Feb;5(2):326.

28.

Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review.

Braithwaite D, Izano M, Moore DH, Kwan ML, Tammemagi MC, Hiatt RA, Kerlikowske K, Kroenke CH, Sweeney C, Habel L, Castillo A, Weltzien E, Caan B.

Breast Cancer Res Treat. 2012 Nov;136(2):521-33. doi: 10.1007/s10549-012-2276-1. Epub 2012 Sep 29. Review.

29.

Benefit of semiannual ipsilateral mammographic surveillance following breast conservation therapy.

Arasu VA, Joe BN, Lvoff NM, Leung JW, Brenner RJ, Flowers CI, Moore DH, Sickles EA.

Radiology. 2012 Aug;264(2):371-7. doi: 10.1148/radiol.12111458. Epub 2012 Jun 12.

30.

Prognostic categories for amyotrophic lateral sclerosis.

Scotton WJ, Scott KM, Moore DH, Almedom L, Wijesekera LC, Janssen A, Nigro C, Sakel M, Leigh PN, Shaw C, Al-Chalabi A.

Amyotroph Lateral Scler. 2012 Oct;13(6):502-8. doi: 10.3109/17482968.2012.679281. Epub 2012 Jun 7.

PMID:
22670880
31.

The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study.

Peled AW, Foster RD, Garwood ER, Moore DH, Ewing CA, Alvarado M, Hwang ES, Esserman LJ.

Plast Reconstr Surg. 2012 Jun;129(6):901e-908e. doi: 10.1097/PRS.0b013e31824ec447.

PMID:
22634688
32.

ACR Appropriateness Criteria® pretreatment planning of invasive cancer of the cervix.

Siegel CL, Andreotti RF, Cardenes HR, Brown DL, Gaffney DK, Horowitz NS, Javitt MC, Lee SI, Mitchell DG, Moore DH, Rao GG, Royal HD, Small W Jr, Varia MA, Yashar CM; American College of Radiology.

J Am Coll Radiol. 2012 Jun;9(6):395-402. doi: 10.1016/j.jacr.2012.02.021.

PMID:
22632665
33.

Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.

Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ.

Ann Surg Oncol. 2012 Nov;19(12):3979-86. doi: 10.1245/s10434-012-2415-2. Epub 2012 May 24.

PMID:
22622474
34.

Prognostic impact of comorbidity among long-term breast cancer survivors: results from the LACE study.

Braithwaite D, Moore DH, Satariano WA, Kwan ML, Hiatt RA, Kroenke C, Caan BJ.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1115-25. doi: 10.1158/1055-9965.EPI-11-1228. Epub 2012 May 9.

35.

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Miller RG, Mitchell JD, Moore DH.

Cochrane Database Syst Rev. 2012 Mar 14;(3):CD001447. doi: 10.1002/14651858.CD001447.pub3. Review.

PMID:
22419278
36.

Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study.

Chase DM, Huang HQ, Wenzel L, Cella D, McQuellon R, Long HJ, Moore DH, Monk BJ.

Gynecol Oncol. 2012 May;125(2):315-9. doi: 10.1016/j.ygyno.2012.01.047. Epub 2012 Feb 1.

PMID:
22307062
37.

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.

Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, Moore DH, Schoenfeld D, Mather JL, Archibald D, Sullivan M, Amburgey C, Moritz J, Gribkoff VK.

Nat Med. 2011 Nov 20;17(12):1652-6. doi: 10.1038/nm.2579.

PMID:
22101764
38.

Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Developed by the Society of Gynecologic Oncology's Clinical Practice Robotics Task Force.

Ramirez PT, Adams S, Boggess JF, Burke WM, Frumovitz MM, Gardner GJ, Havrilesky LJ, Holloway R, Lowe MP, Magrina JF, Moore DH, Soliman PT, Yap S.

Gynecol Oncol. 2012 Feb;124(2):180-4. doi: 10.1016/j.ygyno.2011.11.006. Epub 2011 Nov 10. No abstract available.

PMID:
22079679
39.

A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study.

Moore DH, Ali S, Koh WJ, Michael H, Barnes MN, McCourt CK, Homesley HD, Walker JL.

Gynecol Oncol. 2012 Mar;124(3):529-33. doi: 10.1016/j.ygyno.2011.11.003. Epub 2011 Nov 9.

PMID:
22079361
40.

Impact of mammographic screening on the detection of good and poor prognosis breast cancers.

Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Retèl VP, Mook S, Glas AM, Moore DH, Linn S, van Leeuwen FE, van 't Veer LJ.

Breast Cancer Res Treat. 2011 Dec;130(3):725-34. doi: 10.1007/s10549-011-1748-z. Epub 2011 Sep 4. Review.

41.

Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women.

Goodson WH 3rd, Luciani MG, Sayeed SA, Jaffee IM, Moore DH 2nd, Dairkee SH.

Carcinogenesis. 2011 Nov;32(11):1724-33. doi: 10.1093/carcin/bgr196. Epub 2011 Sep 1.

42.

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design.

Miller RG, Moore DH, Forshew DA, Katz JS, Barohn RJ, Valan M, Bromberg MB, Goslin KL, Graves MC, McCluskey LF, McVey AL, Mozaffar T, Florence JM, Pestronk A, Ross M, Simpson EP, Appel SH; WALS Study Group.

Neurology. 2011 Sep 6;77(10):973-9. doi: 10.1212/WNL.0b013e31822dc7a5. Epub 2011 Aug 3.

43.

Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.

Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ.

Breast Cancer Res Treat. 2011 Nov;130(2):635-44. doi: 10.1007/s10549-011-1646-4. Epub 2011 Jun 30.

PMID:
21717106
44.

Does use of the adjuvant! model influence use of adjuvant therapy through better risk communication?

Belkora JK, Hutton DW, Moore DH, Siminoff LA.

J Natl Compr Canc Netw. 2011 Jul 1;9(7):707-12.

45.

Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.

Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, Moore DH, Ziegler J.

Int J Gynecol Cancer. 2011 Jul;21(5):846-51. doi: 10.1097/IGC.0b013e31821bc7e3.

PMID:
21670699
46.

Impact of decision aids in a sustained implementation at a breast care center.

Belkora JK, Volz S, Teng AE, Moore DH, Loth MK, Sepucha KR.

Patient Educ Couns. 2012 Feb;86(2):195-204. doi: 10.1016/j.pec.2011.05.011. Epub 2011 Jun 12.

PMID:
21665420
47.

Surgical staging of endometrial cancer: robotic versus open technique outcomes in a contemporary single surgeon series.

Goel M, Zollinger TW, Moore DH.

J Robot Surg. 2011 Jun;5(2):109-14. doi: 10.1007/s11701-010-0239-2. Epub 2011 Jan 14.

PMID:
27637536
48.

Biologic markers determine both the risk and the timing of recurrence in breast cancer.

Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC.

Breast Cancer Res Treat. 2011 Sep;129(2):607-16. doi: 10.1007/s10549-011-1564-5. Epub 2011 May 20.

49.

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.

Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC.

Breast Cancer Res. 2010;12(5):R85. doi: 10.1186/bcr2753. Epub 2010 Oct 14.

50.

Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression.

DeLisser H, Liu Y, Desprez PY, Thor A, Briasouli P, Handumrongkul C, Wilfong J, Yount G, Nosrati M, Fong S, Shtivelman E, Fehrenbach M, Cao G, Moore DH, Nayak S, Liggitt D, Kashani-Sabet M, Debs R.

Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18616-21. doi: 10.1073/pnas.1004654107. Epub 2010 Oct 6. Erratum in: Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3821. Nyack, Shruti [corrected to Nayak, Shruti].

Supplemental Content

Loading ...
Support Center